American Home's Enbrel Could Earn $500 Mln a Year, NYT Reports
Bloomberg News
September 16, 1998, 10:05 a.m. ET
Madison, New Jersey, Sept. 16 (Bloomberg) -- American Home
Products Corp. is expected to receive Food and Drug
Administration approval within weeks to market Enbrel, its new
injectable rheumatoid arthritis drug, and analysts project
worldwide sales at over $500 million a year, the New York Times
reported in its ''Market Place'' column. Next year, American Home
plans to begin selling a new gastrointestinal drug, Protonix, and
an immuno-suppression therapy for organ transplants, Rapamune,
with analysts predicting sales for each to top $1 billion a year.
American Home, which recalled its painkiller Duract this year,
could face more troubles, including lawsuits from the ''fen-
phen'' diet drug and possible Federal Trade Commission objections
to its pending acquisition of Monsanto Co., the paper said.
Last week, American Home quietly settled at least two
lawsuits filed by women who claimed that the ''fen-phen'' diet-
drug combination caused their pulmonary hypertension, a rare and
often fatal lung condition.
(NYT 9/16 C7 www.nytimes.com)
--Mary Guidry in the Princeton newsroom (609) 279-4028 /jjs |
